Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies

Author:

Dickinson Laura12,Boffito Marta3,Back David2,Else Laura2,von Hentig Nils4,Davies Geraint2,Khoo Saye2,Pozniak Anton3,Moyle Graeme3,Aarons Leon5

Affiliation:

1. NIHR Biomedical Research Centre, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, United Kingdom

2. Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom

3. St. Stephen's Centre, Chelsea and Westminster Foundation Trust, London, United Kingdom

4. Medical Centre of Johann Wolfgang Goethe University, Frankfurt am Main, Germany

5. School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom

Abstract

ABSTRACT Nonlinear mixed-effects modeling was applied to explore the relationship between lopinavir and ritonavir concentrations over 72 h following drug cessation and also to assess other lopinavir and ritonavir dosing strategies compared to the standard 400-mg–100-mg twice-daily dose. Data from 16 healthy volunteers were included. Possible covariates influencing lopinavir and ritonavir pharmacokinetics were also assessed. Data were modeled first separately and then together by using individually predicted ritonavir pharmacokinetic parameters in the final lopinavir model. The model was evaluated by means of a visual predictive check and external validation. A maximum-effect model in which ritonavir inhibited the elimination of lopinavir best described the relationship between ritonavir concentrations and lopinavir clearance (CL/ F ). A ritonavir concentration of 0.06 mg/liter was associated with a 50% maximum inhibition of the lopinavir CL/ F . The population prediction of the lopinavir CL/ F in the absence of ritonavir was 21.6 liters/h (relative standard error, 14.0%), and the apparent volume of distribution and absorption rate constant were 55.3 liters (relative standard error, 10.2%) and 0.57 h −1 (relative standard error, 0.39%), respectively. Overall, 92% and 94% of the observed concentrations were encompassed by the 95% prediction intervals for lopinavir and ritonavir, respectively, which is indicative of an adequate model. Predictions of concentrations from an external data set (HIV infected) ( n = 12) satisfied predictive performance criteria. Simulated lopinavir exposures at lopinavir-ritonavir doses of 200 mg-150 mg and 200 mg-50 mg twice daily were 38% and 65% lower, respectively, than that of the standard dose. The model allows a better understanding of the interaction between lopinavir and ritonavir and may allow a better prediction of lopinavir concentrations and assessments of different dosing strategies.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference16 articles.

1. Abbott Laboratories. 15 June 2010 accession date. Kaletra (lopinavir/ritonavir) tablets and oral solution. US prescribing information. Abbott Laboratories North Chicago IL. http://www.rxabbott.com/pdf/kaletratabpi.pdf.

2. Abbott Laboratories. 15 June 2010 accession date. Kaletra 200 mg/50 mg film-coated tablets. Summary of product characteristics. Abbott Laboratories North Chicago IL. http://www.medicines.org.uk/emc/medicine/18442.

3. BaldwinJ. R. . 1999. Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, abstr. 657.

4. BealS. SheinerL. B.. 1989–1998. NONMEM users guide. ICON Development Solutions, Ellicott City, MD.

5. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation;Boffito M.;Antivir. Ther,2008

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3